Ultragenyx Pharmaceutical reported $1.31B in Assets for its fiscal quarter ending in June of 2025.


Assets Change Date
Acadia Pharmaceuticals USD 1.23B 93.19M Jun/2025
Agios Pharmaceuticals USD 1.47B 84.28M Jun/2025
Alnylam Pharmaceuticals USD 4.57B 352.21M Jun/2025
BioMarin Pharmaceutical USD 7.46B 309.33M Jun/2025
Insmed USD 2.48B 677.12M Jun/2025
Ionis Pharmaceuticals USD 2.99B 172.18M Jun/2025
Kyowa Hakko Kirin JPY 1.07T 47.23B Jun/2025
MacroGenics USD 245.42M 16.24M Jun/2025
Moderna USD 12.01B 694M Jun/2025
Neurocrine Biosciences USD 3.89B 202.1M Jun/2025
PTC Therapeutics USD 2.63B 21.23M Jun/2025
Regeneron Pharmaceuticals USD 38.22B 674M Jun/2025
Sarepta Therapeutics USD 3.68B 214.43M Jun/2025
Ultragenyx Pharmaceutical USD 1.31B 5.66M Jun/2025
Vertex Pharmaceuticals USD 24.04B 1.16B Jun/2025